Detección inmunohistoquímica de la mutación BRAF V600E en el carcinoma papilar de tiroides. Evaluación frente a la reacción en cadena de la polimerasa en tiempo real

Liu, 2014, The association between BRAFV600E mutation and pathological features in PTC, Eur Arch Otorhinolaryngol, 271, 3041, 10.1007/s00405-013-2872-7 Xing, 2005, BRAF mutation in thyroid cancer, Endocr Relat Cancer, 12, 245, 10.1677/erc.1.0978 Xing, 2015, Association between BRAF V600E mutation and recurrence of papillary thyroid cancer, J Clin Oncol., 33, 42, 10.1200/JCO.2014.56.8253 Haugen, 2016, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid., 26, 1, 10.1089/thy.2015.0020 Cañadas-Garre, 2012, Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAFT1799 a mutation on fine-needle aspiration biopsy specimens. A prospective study of 814 thyroid FNAB patients, Ann Surg., 255, 986, 10.1097/SLA.0b013e31824e8d70 Anderson, 2012, Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tis-sue specimens of malignant melanoma, Arch Pathol Lab Med., 136, 1385, 10.5858/arpa.2011-0505-OA Rowe, 2007, Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis, J Clin Pathol., 60, 1211, 10.1136/jcp.2006.040105 Koperek, 2012, Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma, Am J Surg Pathol., 36, 844, 10.1097/PAS.0b013e318246b527 Lo, 2016, A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma, Br J Cancer., 115, 223, 10.1038/bjc.2016.106 Zagzag, 2013, Clinical utility of immunohistochemistry for the detection of the BRAF V600E mutation in papillary thyroid carcinoma, Surgery., 154, 1199, 10.1016/j.surg.2013.06.020 Martinuzzi, 2016, A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer, Endocrine., 53, 672, 10.1007/s12020-015-0720-9 Sun, 2015, Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma, Int J Clin Exp Pathol., 8, 15072 Van Nederveen, 2009, An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis, Lancet Oncol., 10, 764, 10.1016/S1470-2045(09)70164-0 Nikiforov, 2013, New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers, Clin Cancer Res., 19, 2283, 10.1158/1078-0432.CCR-12-1253 Riesco-Eizaguirre, 2006, The oncogéne BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane, Endocrine-Related Cancer., 13, 257, 10.1677/erc.1.01119 Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;S1470-2045:30166-8. Papathomas, 2015, SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T), Mod Pathol., 28, 807, 10.1038/modpathol.2015.41 Dvorak, 2014, Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma, Pathology, 46, 509, 10.1097/PAT.0000000000000119 Ihle, 2014, Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer., 14, 13, 10.1186/1471-2407-14-13 Jung, 2015, Clinicopathologic correlations of the BRAFV- 600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma, Pathol Res Pract, 211, 162, 10.1016/j.prp.2014.10.005 Crescenzi, 2014, Immunohistochemistry for BRAF(V600E) Antibody VE1 Performed in Core Needle Biopsy Samples Identifies Mutated Papillary Thyroid Cancers, Horm Metab Res, 46, 370, 10.1055/s-0034-1368700 Choi, 2016, Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules, Clin Endocrinol (Oxf)., 84, 607, 10.1111/cen.12866 Zimmermann, 2014, Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma, Cancer Cytopathol., 122, 48, 10.1002/cncy.21352 Pyo, 2015, BRAF Immunohistochemistry using clone VE1 is strongly concordant with BRAF(V600E) mutation test in papillary thyroid carcinoma, Endocr Pathol., 26, 211, 10.1007/s12022-015-9374-7 Capper, 2012, Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases, Acta Neuropathol, 123, 223, 10.1007/s00401-011-0887-y Zhu, 2016, Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma, Exp Mol Pathol., 100, 236, 10.1016/j.yexmp.2016.01.004 Jones, 2015, Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia, Mod Pathol., 28, 596, 10.1038/modpathol.2014.150 De Biase, 2014, High-sensitivity BRAF mutation analysis: bRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas, J Clin Endocrinol Metab., 99, 1530, 10.1210/jc.2013-4389